12:00 AM
Apr 12, 2012
 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information
Acute myelogenous leukemia (AML) B cell lymphoma 2 (BCL-2; BCL2); BCL2-like 11 apoptosis facilitator (BCL2L11; BIM)...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >